Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BlossomHill Therapeutics, Inc.BLSM · Entity 5423 | Director | August 06, 2026 | August 10, 2026 |
| FoxWayne Enterprises Acquisition Corp.FOXW · Entity 143677 | Director | January 19, 2021 | January 20, 2021 |
| PAVmed Inc.PAVM · Entity 7317 | Director | April 02, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BlossomHill Therapeutics, Inc.
Report date August 06, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Brahma BlossomHill Partners, LLC | 578,524 |
Reported balance
After 2026-08-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-10 · Conversion · Acquired 578,524 · Balance 578,524 F1: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The securities are held of record by Brahma BlossomHill Partners, LLC ("Brahma Partners"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-08-05 | Direct | 23,904 |
Reported balance
After 2026-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-06 · Grant · Acquired 23,904 · Balance 23,904 F3: 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Brahma BlossomHill Partners, LLC | 0 |
Reported balance
After 2026-08-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-10 · Conversion · Disposed 578,524 · Balance 0 F1: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: The securities are held of record by Brahma BlossomHill Partners, LLC ("Brahma Partners"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
F2: The securities are held of record by Brahma BlossomHill Partners, LLC ("Brahma Partners"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3: 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026.
FoxWayne Enterprises Acquisition Corp.
Report date January 19, 2021 · Filed January 20, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2021-01-19 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Common Stock will automatically convert into shares of Class A Common Stock at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment. The Class B Common Stock has no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Common Stock will automatically convert into shares of Class A Common Stock at the time of the Issuer's initial business combination on a one-for-one basis, subject to adjustment. The Class B Common Stock has no expiration date.
PAVmed Inc.
Report date April 02, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,337 |
Reported balance
After 2026-04-02 transaction · row 1
1 source rowRow 1 · 2026-04-02 · Grant · Acquired 13,930 · Balance 19,337 F1: Represents restricted stock granted to the reporting person under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock granted to the reporting person under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 10, 2026 22:29 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | ConversionSeries B Preferred Stock · Derivative | 578,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001840599-26-000003 · form4-08102026_100855.xml · derivative · entry 3 Agrawal Sundeep · CIK 0001840599 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brahma BlossomHill Partners, LLC Disclosed balance after: 0 Underlying: Common Stock · 578,524 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · price: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held of record by Brahma BlossomHill Partners, LLC ("Brahma Partners"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 10, 2026 Filed Aug 10, 2026 22:29 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | ConversionCommon Stock | 578,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001840599-26-000003 · form4-08102026_100855.xml · nonDerivative · entry 1 Agrawal Sundeep · CIK 0001840599 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Brahma BlossomHill Partners, LLC Disclosed balance after: 578,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock (the "Preferred Stock") automatically converted into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: The securities are held of record by Brahma BlossomHill Partners, LLC ("Brahma Partners"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Read SEC document |
| August 06, 2026 Filed Aug 10, 2026 22:29 UTC | BlossomHill Therapeutics, Inc. BLSM · Entity 5423 | GrantDirector Stock Option (Right to Buy) · Derivative | 23,904 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001840599-26-000003 · form4-08102026_100855.xml · derivative · entry 2 Agrawal Sundeep · CIK 0001840599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,904 Underlying: Common Stock · 23,904 shares Expires 2036-08-05 F3 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest in equal monthly installments over a three year period following August 6, 2026. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 20:46 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantCommon Stock | 13,930 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-26-000147 · form4.xml · nonDerivative · entry 1 Agrawal Sundeep · CIK 0001840599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,337 F1 · shares: Represents restricted stock granted to the reporting person under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. F1 · price: Represents restricted stock granted to the reporting person under the issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed. Read SEC document |
| September 30, 2025 Filed Oct 2, 2025 20:17 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001094891-25-000042 · form4.xml · nonDerivative · entry 1 Agrawal Sundeep · CIK 0001840599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162,195 F1 · shares: Represents restricted stock granted to the reporting person under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed. F1 · price: Represents restricted stock granted to the reporting person under the issuer's Sixth Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed. Read SEC document |
| October 21, 2024 Filed Oct 23, 2024 20:36 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee stock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.04 | $0.00 |
DisclosureSEC source: 0001062993-24-017897 · form4.xml · derivative · entry 1 Agrawal Sundeep · CIK 0001840599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common stock · 50,000 shares Expires 2034-10-21 F1 · derivative.exercise_date: One third of the option vests on June 30, 2025; the balance vests in eight equal quarterly installments, starting September 30, 2025. Read SEC document |
| September 19, 2024 Filed Sep 20, 2024 20:13 UTC | PAVmed Inc. PAVM · Entity 7317 | GrantEmployee stock option (right to buy) · Derivative | 205,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001062993-24-016841 · form4.xml · derivative · entry 1 Agrawal Sundeep · CIK 0001840599 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,000 Underlying: Common stock · 205,000 shares Expires 2034-09-19 F1 · derivative.exercise_date: One third of the option vests on June 30, 2025; the balance vests in eight equal quarterly installments, starting September 30, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.